Skandinaviska Enskilda Banken AB publ Has $10.40 Million Stock Position in DaVita Inc. $DVA

Skandinaviska Enskilda Banken AB publ reduced its stake in DaVita Inc. (NYSE:DVA) by 37.3% in the 3rd quarter, HoldingsChannel reports. The firm owned 78,293 shares of the company’s stock after selling 46,540 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in DaVita were worth $10,403,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of DVA. Man Group plc raised its holdings in shares of DaVita by 1,608.6% in the second quarter. Man Group plc now owns 285,809 shares of the company’s stock valued at $40,713,000 after purchasing an additional 269,081 shares during the last quarter. Norges Bank bought a new position in shares of DaVita in the second quarter worth $32,986,000. Todd Asset Management LLC bought a new position in shares of DaVita in the third quarter worth approximately $21,842,000. Arrowstreet Capital Limited Partnership raised its position in shares of DaVita by 132.1% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 264,084 shares of the company’s stock valued at $37,619,000 after buying an additional 150,318 shares in the last quarter. Finally, Rakuten Investment Management Inc. bought a new position in DaVita during the third quarter valued at approximately $19,875,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Stock Down 1.8%

DVA stock opened at $147.76 on Thursday. DaVita Inc. has a twelve month low of $101.00 and a twelve month high of $157.12. The business’s fifty day simple moving average is $119.59 and its two-hundred day simple moving average is $125.05. The firm has a market cap of $9.87 billion, a price-to-earnings ratio of 14.91, a PEG ratio of 0.52 and a beta of 0.99.

DaVita (NYSE:DVA) last issued its earnings results on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.24 by $0.16. The company had revenue of $3.62 billion for the quarter, compared to analysts’ expectations of $3.51 billion. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The firm’s quarterly revenue was up 9.9% on a year-over-year basis. During the same period in the prior year, the business earned $2.24 EPS. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. Research analysts expect that DaVita Inc. will post 10.76 EPS for the current year.

Wall Street Analyst Weigh In

DVA has been the topic of a number of recent analyst reports. Zacks Research upgraded DaVita from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. Truist Financial set a $158.00 price target on DaVita in a report on Thursday, February 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a research note on Monday, December 29th. Barclays increased their price objective on shares of DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 3rd. Finally, UBS Group upped their price target on DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a research report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, DaVita currently has a consensus rating of “Hold” and an average target price of $160.50.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.